China state media dismiss Trump's tariff vow, focus on fentanyl
Tariff threat rattles China's industrial complex
Scapegoating cannot end U.S. drug crisis, China Daily says
Some economists have begun downgrading their GDP targets
By Joe Cash
BEIJING, Nov 27 (Reuters) -China's state media shrugged off U.S. President-elect Donald Trump's pledge to slap additional tariffs on Chinese goods in editorials late on Tuesday, accusing the former president of blaming China for the country's failure to address the fentanyl crisis.
Trump, who takes office on Jan. 20, said on Monday he would impose "an additional 10% tariff, above any additional tariffs" on imports from China. He previously said he would introduce tariffs in excess of 60% on Chinese goods.
The tariff threat is rattling China's industrial complex, which sells goods worth more than $400 billion annually to the U.S. and hundreds of billions more in components for products Americans buy from elsewhere.
Economists have begun downgrading their growth targets for the $19 trillion economy for 2025 and 2026.
Editorials in Chinese communist party mouthpieces China Daily and the Global Times focused squarely on the reason Trump gave for imposing the tariffs: fentanyl.
"Scapegoating others can't end U.S.' drug crisis," read the headline of a China Daily editorial on Tuesday, while the Global Times urged the "U.S. not to take China's goodwill for granted regarding anti-drug cooperation after Trump's remarks."
"The excuse the president-elect has given to justify his threat of additional tariffs on imports from China is farfetched," China Daily said. "The world sees clearly that the root cause of the fentanyl crisis in the U.S. lies with the U.S. itself," it added.
"There are no winners in tariff wars. If the U.S. continues to politicise economic and trade issues by weaponising tariffs, it will leave no party unscathed."
Trump's team maintains China is "attacking" the U.S. with fentanyl.
China is the dominant source of chemical precursors used by Mexican cartels to produce the deadly drug. Trump on Monday also pledged 25% tariffs on goods coming from Mexico and Canada until they clamp down on drugs and migrants crossing the border.
Trump is threatening Beijing with far higher tariffs than the 7.5%-25% levied on Chinese goods during his first term.
S&P Global on Sunday lowered its growth forecast for China for 2025 and 2026 by 0.2 and 0.7 percentage point, respectively, to 4.1% and 3.8%, citing the impact Trump's tariffs could have.
"What we assumed in our baseline is an across-the-board increase from around 14% now to 25%. Thus, what we assumed is a bit more than the 10% on all imports from China," said Louis Kuijs, Chief Asia Economist at S&P Global Ratings.
"For now the only thing we know for sure is that the risks in this area are high."
Reporting by Joe Cash; Editing by Jacqueline Wong
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
